AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28026727 — intervention group
Group type: COMPARATOR
Intervention: Decompression alone
Number of subjects: 12
Study 24678939 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 535
Study 24678939 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 535
Study 23272227 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate monotherapy (2 mg/kg/day)
Number of subjects: 126
Study 23272227 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate monotherapy (4 mg/kg/day)
Number of subjects: 126
Study 23272227 — intervention group
Group type: COMPARATOR
Intervention: quinine plus doxycycline TID for 7 days
Number of subjects: 126
Study 23272227 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate monotherapy (2 mg/kg/day) and (4 mg/kg/day)
Number of subjects: 126
Study 19147138 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with previous GDM
Number of subjects: 164
Study 19147138 — intervention group
Group type: COMPARATOR
Intervention: Control group (lean women with negative screening for GDM)
Number of subjects: 164
Study 17071945 — intervention group
Group type: EXPERIMENTAL
Intervention: Bangkok schoolchildren
Number of subjects: 184
Study 15931222 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of oxytocin
Number of subjects: 0
Study 12149762 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (T) with azathioprine and prednisolone
Number of subjects: 40
Study 12149762 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin (C) with azathioprine and prednisolone
Number of subjects: 40
Study 9869669 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (3 cycles of cisplatin and fluorouracil, followed by 2 additional cycles after surgery)
Number of subjects: 440
Study 9869669 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery (surgery alone)
Number of subjects: 440
Study 7613890 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg intravenously 2 h before surgery
Number of subjects: 26
Study 7613890 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole during induction of anaesthesia
Number of subjects: 26
Study 2529072 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 30, 50, or 75 micrograms per dose in 20 ml normal saline solution
Number of subjects: 22
Study 27633 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine edisylate 10mg
Number of subjects: 61
Study 27633 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine hydrochloride 100mg
Number of subjects: 61
Study 27633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 27633 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 61
Study 30460598 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP 140-160 mmHg
Number of subjects: 218
Study 30460598 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP 161-180 mmHg
Number of subjects: 218
Study 30460598 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP 181-200 mmHg
Number of subjects: 218
Study 29181517 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical simulation session using the Eyesi Cataract Surgery Simulator (VRmagic) for 2 hours
Number of subjects: 8
Study 29181517 — intervention group
Group type: COMPARATOR
Intervention: Control session for 2 hours (passive and active tasks)
Number of subjects: 8
Study 24735840 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound tissue characterisation (UTC) imaging on day 0, day 1, day 2, and day 4 postgame
Number of subjects: 18
Study 24735840 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound tissue characterisation (UTC) imaging
Number of subjects: 18
Study 24154513 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol 250/50 µg, twice daily
Number of subjects: 547
Study 24154513 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 µg, twice daily
Number of subjects: 547
Study 24154513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study 21483463 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational booklet
Number of subjects: 436
Study 21483463 — intervention group
Group type: COMPARATOR
Intervention: Usual instructions (Control)
Number of subjects: 436
Study 19394976 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone + metformin
Number of subjects: 271
Study 19394976 — intervention group
Group type: EXPERIMENTAL
Intervention: glimepiride + metformin
Number of subjects: 271
Study 19394976 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone alone
Number of subjects: 271
Study 19394976 — intervention group
Group type: COMPARATOR
Intervention: metformin alone
Number of subjects: 271
Study 17537217 — intervention group
Group type: EXPERIMENTAL
Intervention: extraperitoneal laparoscopic radical prostatectomy (eLRP)
Number of subjects: 403
Study 17537217 — intervention group
Group type: COMPARATOR
Intervention: open retropubic radical prostatectomy (RRP)
Number of subjects: 403
Study 15151693 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic information with details of the expected recovery
Number of subjects: 0
Study 15151693 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic information with details of both the operative procedures and recovery
Number of subjects: 0
Study 15151693 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic information with details of the operative procedures
Number of subjects: 0
Study 15151693 — intervention group
Group type: COMPARATOR
Intervention: Basic information only
Number of subjects: 0
Study 10928463 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel-containing OC (150 microg desogestrel/30 microg ethinylestradiol)
Number of subjects: 28
Study 10928463 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing OC (150 microg levonorgestrel/30 microg ethinylestradiol)
Number of subjects: 28
Study 10928463 — intervention group
Group type: COMPARATOR
Intervention: Comparison of desogestrel vs levonorgestrel
Number of subjects: 28
Study 9483810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (0.03 mg) plus dienogest (2 mg)
Number of subjects: 4
Study 9483810 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest alone (0.5-2 mg/day)
Number of subjects: 4
Study 9483810 — intervention group
Group type: COMPARATOR
Intervention: EE/DNG
Number of subjects: 4
Study 9483810 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential regimen of dienogest, chlormadinone acetate, and desogestrel
Number of subjects: 4
Study 9483810 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethindrone acetate and levonorgestrel
Number of subjects: 4
Study 8141827 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA, mesalazine) 500 mg tid in slow release tablets (Salofalk)
Number of subjects: 18
Study 8141827 — intervention group
Group type: COMPARATOR
Intervention: 5-aminosalicylic acid (5-ASA, mesalazine) 250 mg in slow release tablets (Salofalk)
Number of subjects: 18
Study 3707796 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 2 mg with adrenaline 50 micrograms
Number of subjects: 14
Study 3707796 — intervention group
Group type: COMPARATOR
Intervention: Morphine 2 mg without adrenaline (plain morphine)
Number of subjects: 14
Study 30782172 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (informed that the capsule contained caffeine)
Number of subjects: 4
Study 30782172 — intervention group
Group type: COMPARATOR
Intervention: Control (no substance)
Number of subjects: 4
Study 29157808 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron (15 mg/Bid)
Number of subjects: 60
Study 29157808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25444531 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (10^8 colony-forming units)
Number of subjects: 52
Study 25444531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 23181634 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake SBP/DBP means ≥130/75 mm Hg
Number of subjects: 3344
Study 23181634 — intervention group
Group type: EXPERIMENTAL
Intervention: Asleep SBP/DBP means ≥110/65 mm Hg
Number of subjects: 3344
Study 23181634 — intervention group
Group type: COMPARATOR
Intervention: Awake SBP/DBP means 135/85 mm Hg
Number of subjects: 3344
Study 23181634 — intervention group
Group type: COMPARATOR
Intervention: Asleep SBP/DBP means 120/70 mm Hg
Number of subjects: 3344
Study 23181634 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake SBP/DBP means 120/75 mm Hg
Number of subjects: 3344
Study 23181634 — intervention group
Group type: EXPERIMENTAL
Intervention: Asleep SBP/DBP means 105/60 mm Hg
Number of subjects: 3344
Study 23181634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory SBP/DBP thresholds 15/10 mm Hg lower for patients with diabetes than without diabetes
Number of subjects: 3344
Study 21704300 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative β‐blockers
Number of subjects: 12855
Study 21704300 — intervention group
Group type: COMPARATOR
Intervention: No preoperative β‐blockers
Number of subjects: 12855
Study 19023879 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 10
Study 16838611 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP-Laser treatment
Number of subjects: 151
Study 16838611 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (KTP-Laser + low-pressure TURP)
Number of subjects: 151
Study 12883779 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiresorptive and osteoanabolic drugs for osteoporosis treatment
Number of subjects: 0
Study 12883779 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment instituted during hospitalisation
Number of subjects: 0
Study 12883779 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued treatment monitored by family doctor
Number of subjects: 0
Study 11253344 — intervention group
Group type: EXPERIMENTAL
Intervention: High fixed doses of unfractionated heparin
Number of subjects: 21
Study 11253344 — intervention group
Group type: COMPARATOR
Intervention: Low doses of unfractionated heparin
Number of subjects: 21
Study 11253344 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory agents
Number of subjects: 21
Study 8750460 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life (QOL) end points in oncology clinical trials
Number of subjects: 0
Study 8750460 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life (QOL) instruments
Number of subjects: 0
Study 8750460 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis plan for QOL
Number of subjects: 0
Study 1320907 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous granisetron (40 micrograms/kg)
Number of subjects: 200
Study 1320907 — intervention group
Group type: COMPARATOR
Intervention: Alizapride (4 mg/kg followed by 4 mg/kg at 4 and 8 h post-treatment) plus dexamethasone (8 mg)
Number of subjects: 200
Study 1320907 — intervention group
Group type: COMPARATOR
Intervention: Alizapride plus dexamethasone
Number of subjects: 200
Study 6338383 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 125
Study 6338383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 30972405 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Program intervention, a universally delivered service aimed at promoting healthy behaviours and reducing obesity risk in infants.
Number of subjects: 0
Study 29855986 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761® (120 mg, twice a day)
Number of subjects: 197
Study 29855986 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline (600 mg, twice a day)
Number of subjects: 197
Study 26455794 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 40
Study 24585444 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of green tea (200 mL of 1.5%, w/v)
Number of subjects: 16
Study 24585444 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular intake of green tea (2 × 200 mL 1%, w/v per day for 7 days)
Number of subjects: 16
Study 24585444 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of green tea
Number of subjects: 16
Study 24585444 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular intake of green tea
Number of subjects: 16
Study 21745654 — intervention group
Group type: EXPERIMENTAL
Intervention: Office training group (personal ergonomic training and workstation adjustments)
Number of subjects: 60
Study 21745654 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo-training group (office training + automatic frequent-feedback system with posture photos)
Number of subjects: 60
Study 21745654 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 20808589 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate physical therapy group (n = 16)
Number of subjects: 31
Study 20808589 — intervention group
Group type: COMPARATOR
Intervention: Delayed physical therapy group (n = 15)
Number of subjects: 31
Study 20808589 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 17667480 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly medicated
Number of subjects: 370
Study 17667480 — intervention group
Group type: COMPARATOR
Intervention: Not medicated
Number of subjects: 370
Study 16103667 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron + Alprazolam (G+A)
Number of subjects: 19
Study 16103667 — intervention group
Group type: COMPARATOR
Intervention: Granisetron alone (G)
Number of subjects: 19
Study 12186662 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet history interviews and three‐day weighed food records administered at one‐month intervals in trial 1
Number of subjects: 91
Study 12186662 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet history interviews and three‐day weighed food records administered at three‐month intervals in trial 2
Number of subjects: 91
Study 12186662 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 91
Study 10195338 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated with neuroleptics
Number of subjects: 59
Study 10195338 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmedicated schizophrenic patients
Number of subjects: 59
Study 10195338 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 59
Study 7757355 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuron-specific enolase (NSE) measurements in patients with pulmonary cancer and other diseases
Number of subjects: 10
Study 7757355 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuron-specific enolase (NSE) measurements in pregnant patients
Number of subjects: 10
Study 7757355 — intervention group
Group type: COMPARATOR
Intervention: Neuron-specific enolase (NSE) measurements in healthy controls
Number of subjects: 10
Study 1430700 — intervention group
Group type: EXPERIMENTAL
Intervention: Statis extracts
Number of subjects: 3
Study 6376235 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Trestatin
Number of subjects: 13
Study 6376235 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Trestatin
Number of subjects: 13
Study 6376235 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg Trestatin
Number of subjects: 13
Study 6376235 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Trestatin
Number of subjects: 13
Study 6376235 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Trestatin (diabetic patients)
Number of subjects: 13
Study 6376235 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Trestatin (diabetic patients)
Number of subjects: 13
Study 6376235 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal subjects)
Number of subjects: 13
Study 6376235 — intervention group
Group type: COMPARATOR
Intervention: Placebo (diabetic patients)
Number of subjects: 13
Study 30741623 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone therapy
Number of subjects: 11508
Study 30741623 — intervention group
Group type: COMPARATOR
Intervention: Control (no edaravone therapy)
Number of subjects: 11508
Study 30244190 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate invasive coronary strategy in conscious OHCA survivors
Number of subjects: 86
Study 30244190 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI in STEMI patients without OHCA
Number of subjects: 86
Study 26598090 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg 3 times/day
Number of subjects: 53
Study 26598090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 23491928 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intravenous SAMe treatment (1,000mg for seven days)
Number of subjects: 79
Study 23491928 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardized treatment)
Number of subjects: 79
Study 23491928 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intravenous SAMe treatment
Number of subjects: 79
Study 21652619 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy (800/100 mg once daily)
Number of subjects: 256
Study 21652619 — intervention group
Group type: COMPARATOR
Intervention: Darunavir/ritonavir plus two nucleoside analogues
Number of subjects: 256
Study 21652619 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 256
Study 20002740 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeomin® treatment
Number of subjects: 100
Study 16440533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate hydrofluoroalkane inhalation aerosol, 88 microg twice daily
Number of subjects: 0
Study 16440533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate hydrofluoroalkane inhalation aerosol, 220 microg twice daily
Number of subjects: 0
Study 16440533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate hydrofluoroalkane inhalation aerosol, 440 microg twice daily
Number of subjects: 0
Study 16440533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16440533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate hydrofluoroalkane inhalation aerosol (all doses)
Number of subjects: 0
Study 14763718 — intervention group
Group type: EXPERIMENTAL
Intervention: Community stroke team rehabilitation
Number of subjects: 421
Study 14763718 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 421
Study 11386892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride (60 mg daily)
Number of subjects: 530
Study 11386892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 9362431 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (standard combination regimens such as cyclophosphamide, methotrexate, and 5-fluorouracil; cyclophosphamide, doxorubicin, and 5-fluorouracil; mitoxantrone and 5-FU; single agents including paclitaxel and docetaxel)
Number of subjects: 195
Study 9362431 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (aminoglutethimide, medroxyprogesterone acetate, tamoxifen, newer aromatase inhibitors such as anastrozole, fadrozole, and letrozole, megestrol acetate)
Number of subjects: 195
Study 9362431 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 195
Study 1382676 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of zolpidem (Stilnox)
Number of subjects: 8
Study 1382676 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed bedtime (3 a.m.)
Number of subjects: 8
Study 1382676 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (2 nights)
Number of subjects: 8
Study 1382676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 4054135 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation (R) group
Number of subjects: 167
Study 4054135 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 167
Study 31260833 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Number of subjects: 3382
Study 31260833 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography (CXR)
Number of subjects: 3382
Study 31260833 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality with LDCT
Number of subjects: 3382
Study 31260833 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality with CXR
Number of subjects: 3382
Study 29530371 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor Sleepers (upper quartile on CSHQ‐ASD)
Number of subjects: 177
Study 29530371 — intervention group
Group type: COMPARATOR
Intervention: Good Sleepers (lower quartile on CSHQ‐ASD)
Number of subjects: 177
Study 25940151 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI therapy for 5 weeks after endoscopic resection (ER)
Number of subjects: 229
Study 25157724 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention
Number of subjects: 101
Study 25157724 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 101
Study 22681603 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) with elastic knee wraps (KW) during leg extensions at 30% 1RM until failure
Number of subjects: 13
Study 22681603 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group without blood flow restriction
Number of subjects: 13
Study 20454491 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 205
Study 20454491 — intervention group
Group type: COMPARATOR
Intervention: Extracapsular cataract extraction
Number of subjects: 205
Study 20454491 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification (working patients)
Number of subjects: 205
Study 20454491 — intervention group
Group type: COMPARATOR
Intervention: Extracapsular cataract extraction (working patients)
Number of subjects: 205
Study 20454491 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification vs Extracapsular cataract extraction
Number of subjects: 205
Study 18586835 — intervention group
Group type: EXPERIMENTAL
Intervention: FLGTN-HUT (800 mcg, metred spray)
Number of subjects: 149
Study 18586835 — intervention group
Group type: COMPARATOR
Intervention: HUT (standard 40-min passive tilt)
Number of subjects: 149
Study 16133387 — intervention group
Group type: EXPERIMENTAL
Intervention: CT correction
Number of subjects: 122